DHR vs STRO · P/E 39, rev $24.57B vs rev $62.0M
Danaher Corporation (DHR) versus Sutro Biopharma (STRO) — a side-by-side from cached financials, not a winner call.
Danaher Corporation (DHR) is a diagnostics & research company listed on US.
Sutro Biopharma (STRO) is a biotechnology company listed on NASDAQ.
Latest reported DHR revenue for 2025-12-31 was $24.57B. Net income was $3.61B. Revenue was up 2.9% from 2024-12-31 to 2025-12-31. DHR currently screens at market cap $144.18B and trailing P/E 39.0.
Latest reported STRO revenue for 2024-12-31 was $62.0M. Net income was -$227.5M. Revenue was down 59.6% from 2023-12-31 to 2024-12-31. STRO currently screens at market cap $470.8M.
DHR currently screens at market cap $144.18B and trailing P/E 39.0. STRO currently screens at market cap $470.8M.
Not investment advice. Open the DHR and STRO stock pages for the full models.
Not investment advice.